HOTH - Hoth granted approval to initiate phase 1b trial to treat atopic dermatitis

Hoth Therapeutics, Inc. (HOTH) has been granted the approval to advance its Phase 1b clinical trial of BioLexa Lotion for the treatment of mild to moderate atopic dermatitis in Australia.The approval by the Human Research Ethics Committee in Australia is a “critical milestone towards initiating our Phase 1b clinical trial in Australia," stated Robb Knie, Chairman and CEO of Hoth Therapeutics, who added that the rigorous guidelines of the HREC ”will support the submission of our full data set upon successful completion of this Phase 1b and our upcoming Phase 2 trial to the FDA”.Conducted in two parts, the randomized, double-blind, parallel-design, placebo-controlled study, will have Part 1, which will be conducted in healthy subjects. Part 2 that includes adult patients with mild to moderate atopic dermatitis will follow the review of the Part 1 safety data.Expecting to dose the first subject during early 2021, the company anticipate the top-line

For further details see:

Hoth granted approval to initiate phase 1b trial to treat atopic dermatitis